Citations Appearing in 1994

  1. Balthasar, J. and H.L. Fung. Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy studies using Digoxin as a model drug. Journal of Pharmacology and Experimental Therapeutics 268:734-739, 1994.
  2. Bever, C.T., D. Young, P.A. Anderson, A. Krumholz, K. Conway, J. Leslie, N. Eddington, K.I. Plaisance, H.S. Panitch, S. Dhibjalbut, M.J. Fossler, J. Devane and K.P. Johnson. The effects of 4-Aminopyridine in multiple sclerosis patients – results of a randomized, placebo controlled, double blind, concentration controlled, crossover trial. Neurology 44:1054-1059, 1994.
  3. Bilello, J.A., J.L. Eiseman, H.C. Standiford and G.L. Drusano. Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrobial Agents and Chemotherapy 38:628-631, 1994.
  4. Burstein, A.H., L.E. Wyble, P. Gal, P.R. Diaz, J.L. Ransom, R.Q. Carlos and A. Forrest. Ticarcillin Clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis. Antimicrobial Agents and Chemotherapy 38:2024-2028, 1994.
  5. Crom, W.R., S.S.N. Degraaf, T. Synold, D.R.A. Uges, H. Bloemhof, G. Rivera, M.L. Christensen, H. Mahmoud and W.E. Evans. Pharmacokinetics of Vincristine in children and adolescents with acute lymphocytic leukemia. Journal of Pediatrics 125:642- 649, 1994.
  6. Drusano, G.L., A. Forrest, G. Yuen, K. Plaisance and J. Leslie. Optimal sampling theory – effect of error in a nominal parameter value on bias and precision of parameter estimation. Journal of Clinical Pharmacology 34:967-974, 1994.
  7. Ducharame, J., I.W. Wainer, H.I. Parenteau and J.H. Rodman. Stereoselective distribution of hydroxychloroquine in the rabbit following single and multiple oral doses of racemate and separate enantiomers. Chirality 6:337-346, 1994.
  8. Eiseman, J.L., N.D. Eddington, J. Leslie, C. Macauley, D.L. Sentz, M. Zuhowski, J.M. Kujawa, D. Young and M.J. Egorin. Plasma pharmacokinetics and tissue distribution of Paclitaxel in CD2F1Mice. Cancer Chemotherapy and Pharmacology 34:465-471, 1994.
  9. Falloon, J., J. Lavelle, D. Ogataarakaki, A. Byrne, A. Graziani, A. Morgan, M.A. Amantea, K. Ownby, M. Polis, R.T. Davey, J.A. Kovacs, H.C. Lane, H. Masur and R.R. Macgregor. Pharmacokinetics and safety of weekly Dapsone and Dapsone plus Pyrimethamine for prevention of pneumocystis pneumonia. Antimicrobial Agents and Chemotherapy 38:1580-1587, 1994.
  10. Fassos, F.F., J. Klein, D. Fernandes, D. Matsui, N.F. Olivieri and G. Koren. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2- Dimethyl-3-Hydroxypyrid-4-one in patients with homozygous beta thalassemia. Clinical Pharmacology and Therapeutics 55:70-75, 1994.
  11. Fletcher, C.V., A.C. Collier, F.S. Rhame, D. Bennett, M.F. Para, C.C. Beatty, C.E. Jones and H.H. Balfour. Foscarnet for suppression of human immunodeficiency virus replication. Antimicrobial Agents and Chemotherapy 38:604-607, 1994.
  12. Friedrich, L.V., R.L. White, M.B. Kays and D.S. Burgess. Drug degradation during HPLC analysis of Aztreonam-effect on pharmacokinetic parameter estimation. Annals of Pharmacotherapy 28:444-446, 1994.
  13. Goss, T.F., A. Forrest, D.E. Nix, C.H. Ballow, M.C. Birmingham, T.J. Cumbo and J.J. Schentag. Mathematical examination of dual individualization principles .2. the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for Ciprofloxacin than for Cefmenoxime. Annals of Pharmacotherapy 28:863-868, 1994.
  14. Gurugrangan, S., M. Horner, J.H. Rodman and N. Marina. Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis. Medical and Pediatric Oncology 22:414-416, 1994.
  15. Hutchaleelaha, A., J. Sukbuntherng, H.H. Chow and M. Mayersohn. Disposition kinetics of D-Amphetamine and L-Amphetamine following intravenous administration of racemic amphetamine to rats. Drug Metabolism and Disposition 22:406-411, 1994.
  16. Johansen, P.B., S.N. Rasmussen and P.B. Ostergaard. Pharmacokinetics of Tinzaparin (Logipar-in(R))-a low molecular weight heparin after single and repeated intravenous administration in rats. Thrombosis Research 75:453-464, 1994.
  17. Jodrell, D.I., L.M. Reyno, R. Sridhara, M.A. Eisenberger, K.H. Tkaczuk, E.G. Zuhowski, V.J. Sinibaldi, M.J. Novak and M.J. Egorin. Suramin: Development of a population pharmacokinetic model and its use with intermittent short (1 hour) infusions to control plasma drug concentration. Journal of Clinical Oncology 12:166-175, 1994.
  18. Kearns, C.M., R.L. Blakley, V.M. Santana and W.R. Crom. Pharmacokinetics of Cladribine (2-Chlorodeoxyadenosine) in children with acute leukemia. Cancer Research 54:1235-1239, 1994.
  19. Kobayashi, K., D.I. Jodrell and M.J. Ratain. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surveys 17:51-78, 1994.
  20. Levy, G., W.F. Ebling and A. Forrest. Concentration controlled or effect controlled clinical trials with sparse data. Clinical Pharmacology and Therapeutics 56:1-8, 1994.
  21. Madden, T. Pharmacokinetics and pharmacodynamics of platinum anti-cancer drugs: determination of intermediate endpoints in the treatment of cancer. Cancer Bulletin 46:21-25, 1994.
  22. Marina, N.M., J.H. Rodman, D.J. Murray, S.J. Sheman, L.C. Bowman, P.P. Jones, W.L. Furman, W.H. Meyer and C.B. Pratt. Phase I study of escalating target doses of Carboplatin combined with Ifofamide in newly diagnosed pediatric solid tumors. Journal of the Cancer Institute 86:544-548, 1994.
  23. Modamio, P., C.F. Lastra and E.L. Marino. Determination of Celiprolol by high performance liquid chromatography and stability in solution. International Journal of Pharmaceutics 107:243-245, 1994.
  24. Modamio, P., O. Montejo, C.F. Lastra and E.L. Marino. A valid high performance liquid chromatography method for Oxprenolol stability studies. International Journal of Pharmaceutics 112:93-96, 1994.
  25. Moore, M.J., C. Erlichman, J.J. Thiessen, P.S. Bunting, R. Hardy, I. Kerr and S. Soldin. Variability in the pharmacokinetics of Cyclophosphamide, Methotrexate and 5- Fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemotherapy and Pharmacology 33:472-476, 1994.
  26. Neef, C., R.W. Jelliffe, T. van Laar, T. Loohuis, A.W.G. Essink and E.N.H. Hansen. Population pharmacokinetics of Apomorphine in patients with Parkinson’s disease. Drug Investigation 7(4):183-190, 1994.
  27. Phillips, D.R., P.J. Moate and R.C. Boston. A modeling procedure for the analysis of dynamic drug DNA interactions probed during active transcription of the DNA. Anti-Cancer Drug Design 9:209-219, 1994.
  28. Piotrovskij, V.K., G. Paintaud, G. Alvan and T. Trnovec. Modeling of the saturable time constrained Amoxicillin absorption in humans. Pharmaceutical Research 11:1346- 1351, 1994.
  29. Pratt, C.B., C. Stewart, V.M. Santana, L. Bowman, W. Furman, J. Ochs, N. Marina, J.F. Kuttesch, R. Heideman, J.T. Sandlund, L. Avery and W.H. Meyer. Phase-I study of Topotecan for pediatric patients with malignant solid tumors. Journal of Clinical Oncology 12:539-543, 1994.
  30. Relling, M.V., R.R. Evans, S. Groom, W.R. Crom and C.B. Pratt. Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 21:639-651, 1994.
  31. Relling, M.V., H.L. Mcleod, L.C. Bowman and V.M. Santana. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to Cisplatin. Clinical Pharmacology and Therapeutics 56:503-511, 1994.
  32. Rodman, J.H., D.J. Murry, T. Madden and V.M. Santana. Altered Etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. Journal of Clinical Oncology 12:2390-2397, 1994.
  33. Ross, D.D., P.J. Wooten, Y. Tong, B. Cornblatt, C. Levy, R. Sridhara, E.J. Lee and C.A. Schiffer. Synergistic reversal of multidrug resistance phenotype in acute myeloid leukemia cells by Cyclosporine A and Cremophor El. Blood 83:1337-1347, 1994.
  34. Rushing, D.A., S.R. Raber, K.A. Rodvold, S.C. Piscitelli, G.S. Plank and D.A. Tewksbury. The effects of Cyclosporine on the pharmacokinetics of Doxorubicin in patients with small cell lung cancer. Cancer 74:834-841, 1994.
  35. Stewart, C.F., S.D. Baker, R.L. Heideman, D. Jones, W.R. Crom and C.B. Pratt. Clinical pharmacodynamics of continuous infusion Topotecan in children systemic exposure predicts hematologic toxicity. Journal of Clinical Oncology 12:1946-1954, 1994.
  36. Synold, T.W., M.V. Relling, J.M. Boyett, G.K. Rivera, J.T. Sandlund, H. Mahmoud, W.M. Crist, C.H. Pui and W.E. Evans. Blast cell methotrexate polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. Journal of Clinical Investigation 94:1996-2001, 1994.
  37. Thomaseth K. Pansym A symbolic equation generator for mathematical modeling, analysis and control of metabolic and pharmacokinetic systems. Computer Methods and Programs in Biomedicine 42:99-112, 1994.
  38. Tod, M., C. Padoin, K. Louchahi, B. Moreautod, O. Petitjean and G. Perret. Application of optimal sampling theory to the determination of Metacycline pharmacokinetic parameters – effect of model misspecification. Journal of Pharmacokinetics and Biopharmaceutics 22:129-146, 1994.
  39. Wilson, J.T., G.L. Kearns, D. Murphy and S.J. Yaffe. Pediatric labeling requirements – implications for pharmacokinetic studies. Clinical Pharmacokinetics 26:308-325, 1994.
  40. Yiamouyiannis, C.A., A. Harris, R.A. Sanders, B.J. Martin and J.B. Watkins. Paracetamol pharmacokinetics are independent of caloric intake and physical activity. Drug Investigation 8:361-368, 1994.